Table 2

Effects of subsequent treatment with VAs on the response to PKC activators (in the ongoing presence of PMA/DOG) in oocytes expressing α1Eβ1Bα2/δ-subunits (schedule 2)

TreatmentIBaChangen
PeakLatePeakLate
nA %
PMA (500 nM)
 Control−2277  ± 601−349  ± 908
 PMA−3144  ± 667−991  ± 23149  ± 9** 207  ± 26**
 HAL (0.59 mM) + PMA−1782  ± 501−466  ± 99−47  ± 62-165 2-a −52  ± 22-165
 Control−1813  ± 396−230  ± 318
 PMA−2767  ± 492−667  ± 9269  ± 132-150 204  ± 27**
 ISO (0.70 mM) + PMA−1194  ± 229−361  ± 40−56  ± 82-165 2-a −42  ± 62-165
DOG (100 μM)
 Control−1979  ± 641−334  ± 1216
 DOG−2706  ± 779−706  ± 24351  ± 102-150 115  ± 202-150
 HAL (0.59 mM) + DOG−1310  ± 417−344  ± 129−55  ± 42-165 2-a −53  ± 32-165

The oocytes were held at −80 mV and depolarized to 0 mV. The control measurements were taken at least 5 min after the oocytes were impaled. The treatment schedule is as shown in schedule 2. Briefly, after obtaining maximum potentiation with PMA or DOG as mentioned in the legends to Fig. 2, the oocytes were perfused with a solution containing VA (in the presence of PMA or DOG). The IBa was recorded after 2 min from the beginning of perfusion with VA. This was followed by the wash protocol. Refer to Fig. 2 for the prototype current tracings for the values shown here. Values are given as mean ± S.E.

  • ↵2-a Percent of PMA- or DOG-enhanced current.

  • ↵2-150  P < .01, ** P < .001, compared with the respective control, paired t test.

  • ↵2-165  P < .001, compared with the respective PMA or DOG, paired t test.